💧 Updated March 2026

Sjogren's Syndrome
Clinical Trials

B cell-depleting therapies, type I interferon inhibitors, and novel immunomodulatory agents are actively recruiting primary Sjogren's patients. Search below and get a plain-English summary of any study.

100+
Sjogren's trials currently recruiting
$0
Cost to participants in most trials
Phase 2/3
Multiple late-stage trials active
Live from ClinicalTrials.gov
Find Sjogren's Trials Near You

Who Is Eligible for Sjogren's Syndrome Trials?

Most Sjogren's trials require a confirmed primary Sjogren's diagnosis per 2016 ACR/EULAR criteria, with active disease measured by the ESSDAI (EULAR Sjogren's Syndrome Disease Activity Index). A minimum ESSDAI score is typically required — usually 5 or above — indicating systemic involvement beyond dryness alone. Anti-SSA/Ro positivity is required in the majority of trials, reflecting the autoantibody profile associated with systemic disease activity.

What Treatments Are Being Tested?

Drug ClassHow It WorksWho It Is For
CD20 B cell depletors Deplete autoreactive B cells driving Sjogren's autoimmunity — obinutuzumab and others Active systemic Sjogren's, ESSDAI 5+
BAFF/BLyS inhibitors Block B cell survival signals — ianalumab and similar agents Anti-SSA positive primary Sjogren's
Type I interferon inhibitors Target the interferon pathway overactive in most Sjogren's patients Sjogren's with positive interferon signature
JAK inhibitors Oral agents targeting JAK-STAT signaling driving glandular and systemic inflammation Active Sjogren's, often with fatigue and joint involvement
IL-6 pathway inhibitors Block IL-6, which drives systemic inflammation and B cell activation in Sjogren's Systemic Sjogren's with elevated inflammatory markers

What to Expect as a Trial Participant

Sjogren's trials typically run 24-48 weeks. Disease activity is assessed using the ESSDAI at each visit. Glandular function may be measured by salivary flow rate, Schirmer test, or minor salivary gland biopsy.

Related Tool
2016 ACR/EULAR Sjogren's Classification Calculator
Check whether your symptoms and tests meet the formal criteria for primary Sjogren's syndrome — the same criteria trial coordinators use for eligibility.
Open Calculator

Frequently Asked Questions

Adults with confirmed primary Sjogren's per 2016 ACR/EULAR criteria and active systemic disease (ESSDAI 5+) are the core population. Most trials require anti-SSA/Ro positivity. Patients with symptoms beyond dryness — fatigue, joint pain, neuropathy — are typically better candidates for systemic disease trials.
Many trials require ESSDAI 5+, which means systemic involvement beyond glandular dryness. However, there are dedicated trials for glandular symptoms, sicca symptoms, and fatigue. Search above and look for trials targeting specific symptom domains.
For most systemic disease trials, yes. Anti-SSA/Ro positivity is the most reliable biomarker of systemic Sjogren's activity and is required in the majority of Phase 3 trials. Some symptom-focused trials may not require it.
Yes. Fatigue is one of the most debilitating symptoms and several trials have fatigue as a primary endpoint alongside disease activity. JAK inhibitors and IL-6 inhibitors in particular are being tested for fatigue relief.
Most run 24-48 weeks for the main phase. Some offer open-label extensions. Infusion-based trials have less frequent visits; oral agents typically require monthly visits.
Most dedicated Sjogren's trials require primary Sjogren's without another connective tissue disease. If you have secondary Sjogren's, you may be better served by trials for your primary condition. Ask your rheumatologist which category applies to you.

Other Rheumatology Trials

Trial data sourced live from ClinicalTrials.gov. Content reviewed by Mahiar Rabie, MS, MD. This page is for informational purposes only and does not constitute medical advice. Eligibility for any specific trial must be confirmed with the trial coordinator.